Skip to main content

Table 5 Most Frequently Reported On-Treatment AEs (≥5% Incidence in Any Treatment Group)

From: CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

 Number of participants, n (%)
Adverse Event
(Preferred term)
Placebo
N = 102
DNX
5 mg
N = 102
DNX
10 mg
N = 103
DNX
25 mg
N = 103
DNX
35 mg
N = 102
DNX
50 mg
N = 102
Any event63 (62)63 (62)69 (67)68 (66)63 (62)71 (70)
Nasopharyngitis12 (12)8 (8)9 (9)12 (12)14 (14)10 (10)
Upper respiratory tract infection5 (5)7 (7)7 (7)9 (9)5 (5)6 (6)
Back pain4 (4)7 (7)4 (4)6 (6)5 (5)5 (5)
Headache2 (2)4 (4)6 (6)5 (5)8 (8)8 (8)
Arthralgia2 (2)05 (5)1 (< 1)2 (2)4 (4)
Cough1 (< 1)4 (4)1 (< 1)2 (2)1 (< 1)5 (5)
Pneumonia1 (< 1)1 (< 1)2 (2)2 (2)1 (< 1)5 (5)